Recro Pharma Inc. (REPH) Stock Price Up 7.1%
Recro Pharma Inc. (NASDAQ:REPH)’s share price rose 7.1% on Monday . The stock traded as high as $10.85 and last traded at $9.80, with a volume of 149,949 shares changing hands. The stock had previously closed at $9.15.
REPH has been the subject of several analyst reports. Brean Capital restated a “buy” rating and set a $28.00 price target on shares of Recro Pharma in a report on Friday, May 13th. HC Wainwright reaffirmed a “buy” rating on shares of Recro Pharma in a research report on Saturday, May 14th. Zacks Investment Research cut Recro Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Finally, Janney Montgomery Scott started coverage on Recro Pharma in a research report on Monday. They set a “buy” rating and a $21.00 price objective on the stock.
The firm’s market cap is $93.06 million. The company’s 50 day moving average is $8.75 and its 200-day moving average is $7.48.
Recro Pharma (NASDAQ:REPH) last issued its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. The business earned $17.30 million during the quarter, compared to analyst estimates of $18.70 million. Equities analysts predict that Recro Pharma Inc. will post ($3.44) EPS for the current fiscal year.
In other news, major shareholder Healthcare Master Fun Broadfin bought 390,000 shares of the stock in a transaction on Tuesday, August 16th. The stock was acquired at an average cost of $7.50 per share, for a total transaction of $2,925,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery. The Company’s lead product is an intranasal formulation of Dexmedetomidine (Dex). Its product candidates for pain indications include: Dex-IN, Dex-SL and Fadolmidine (Fado).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.